{"id":"27116427434-57","name":"Teva Pharmaceuticals Europe BV","registrationDate":"2011-12-14T15:34:05.624+02:00","category":2,"subCategory":3,"legal":"BV","web":"http://www.tevapharm.com","country":"Netherlands","headAddress":"PIET HEINKADE, 107","headCity":"Amsterdam","headPostCode":"1019","headPhone":"(31)02 02 19 30 00","boss":"Richard Daniell","bossTitle":"Mr","bossPosition":"President and CEO, Teva Pharmaceuticals Europe BV","membersCount":4,"membersFTE":"2.25","membership":"Medicines for Europe &#xd;\nEFPIA (as from September 2016)&#xd;\nEUCOPE &#xd;\nFriends of Europe&#xd;\nAECA&#xd;\nEPF","memberOrga":"","goal":"Established in 1901, Teva is a global generic pharmaceuticals leader and one of the top 10 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide, of which more than 54,000 in the European Union.&#xd;<br /> &#xd;<br />Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API).","acronym":"Teva","interests":"Business and Industry, Competition, Consumers, Customs, Digital economy and society, Economy, finance and the euro, Enlargement, Environment, External Relations, Humanitarian aid and civil protection, Justice and Fundamental Rights, Public Health, Research and innovation, Single market, Trade","euInitiatives":"Public Health, Industrial and IP Policies, Pricing and Reimbursement Policies, Pharmaceutical legislation, European external trade agenda, European semester, global health.","lastUp":"2018-04-30T12:12:25.740+02:00","customers":"","costAbsolu":"","costRange":"600000-699999","turnoverAbsolu":0,"turnoverRange":""}